Cargando…
Effectiveness, treatment durability, and treatment costs of canagliflozin and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes in the USA
INTRODUCTION: This real-world study compared glycemic effectiveness, treatment durability, and treatment costs with canagliflozin 300 mg versus any dose of glucagon-like peptide-1 (GLP-1) receptor agonists in patients with type 2 diabetes mellitus (T2DM) in the USA. RESEARCH DESIGN AND METHODS: A re...
Autores principales: | Singhal, Mukul, Tan, Hiangkiat, Coleman, Craig I, Han, Michelle, Nguyen, Chi, Ingham, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861096/ https://www.ncbi.nlm.nih.gov/pubmed/31798890 http://dx.doi.org/10.1136/bmjdrc-2019-000704 |
Ejemplares similares
-
Glucagon-like peptide 1 agonists for treatment of patients with type 2 diabetes who fail metformin monotherapy: systematic review and meta-analysis of economic evaluation studies
por: Bagepally, Bhavani Shankara, et al.
Publicado: (2020) -
Association Between Glucagon-Like Peptide 1 Receptor Agonist and Sodium–Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes
por: Kahkoska, Anna R., et al.
Publicado: (2021) -
Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes
por: Sherr, Jennifer L., et al.
Publicado: (2016) -
Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study
por: Rickels, Michael R., et al.
Publicado: (2016) -
Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)